tetano
Editor, Senior Moderator
Molecules
. 2020 Nov 13;25(22):E5291.
doi: 10.3390/molecules25225291.
Identification of Novel Influenza Polymerase PB2 Inhibitors Using a Cascade Docking Virtual Screening Approach
Lei Zhao[SUP] 1 [/SUP], Jinjing Che[SUP] 1 [/SUP], Qian Zhang[SUP] 2 [/SUP], Yiming Li[SUP] 3 [/SUP], Xiaojia Guo[SUP] 1 [/SUP], Lixia Chen[SUP] 4 [/SUP], Hua Li[SUP] 5 [/SUP], Ruiyuan Cao[SUP] 1 [/SUP], Xingzhou Li[SUP] 1 [/SUP]
Affiliations
Abstract
To discover novel inhibitors that target the influenza polymerase basic protein 2 (PB2) cap-binding domain (CBD), commercial ChemBridge compound libraries containing 384,796 compounds were screened using a cascade docking of LibDock-LigandFit-GOLD, and 60 compounds were selected for testing with cytopathic effect (CPE) inhibition assays and surface plasmon resonance (SPR) assay. Ten compounds were identified to rescue cells from H1N1 virus-mediated death at non-cytotoxic concentrations with EC[SUB]50[/SUB] values ranging from 0.30 to 67.65 μM and could bind to the PB2 CBD of H1N1 with Kd values ranging from 0.21 to 6.77 μM. Among these, four compounds (11D4, 12C5, 21A5, and 21B1) showed inhibition of a broad spectrum of influenza virus strains, including oseltamivir-resistant ones, the PR/8-R292K mutant (H1N1, recombinant oseltamivir-resistant strain), the PR/8-I38T mutant (H1N1, recombinant baloxavir-resistant strain), and the influenza B/Lee/40 virus strain. These compounds have novel chemical scaffolds and relatively small molecular weights and are suitable for optimization as lead compounds. Based on sequence and structure comparisons of PB2 CBDs of various influenza virus subtypes, we propose that the Phe323/Gln325, Asn429/Ser431, and Arg355/Gly357 mutations, particularly the Arg355/Gly357 mutation, have a marked impact on the selectivities of PB2 CBD-targeted inhibitors of influenza A and influenza B.
Keywords: influenza virus; inhibitor; polymerase basic protein 2; virtual screening.
. 2020 Nov 13;25(22):E5291.
doi: 10.3390/molecules25225291.
Identification of Novel Influenza Polymerase PB2 Inhibitors Using a Cascade Docking Virtual Screening Approach
Lei Zhao[SUP] 1 [/SUP], Jinjing Che[SUP] 1 [/SUP], Qian Zhang[SUP] 2 [/SUP], Yiming Li[SUP] 3 [/SUP], Xiaojia Guo[SUP] 1 [/SUP], Lixia Chen[SUP] 4 [/SUP], Hua Li[SUP] 5 [/SUP], Ruiyuan Cao[SUP] 1 [/SUP], Xingzhou Li[SUP] 1 [/SUP]
Affiliations
- PMID: 33202790
- DOI: 10.3390/molecules25225291
Abstract
To discover novel inhibitors that target the influenza polymerase basic protein 2 (PB2) cap-binding domain (CBD), commercial ChemBridge compound libraries containing 384,796 compounds were screened using a cascade docking of LibDock-LigandFit-GOLD, and 60 compounds were selected for testing with cytopathic effect (CPE) inhibition assays and surface plasmon resonance (SPR) assay. Ten compounds were identified to rescue cells from H1N1 virus-mediated death at non-cytotoxic concentrations with EC[SUB]50[/SUB] values ranging from 0.30 to 67.65 μM and could bind to the PB2 CBD of H1N1 with Kd values ranging from 0.21 to 6.77 μM. Among these, four compounds (11D4, 12C5, 21A5, and 21B1) showed inhibition of a broad spectrum of influenza virus strains, including oseltamivir-resistant ones, the PR/8-R292K mutant (H1N1, recombinant oseltamivir-resistant strain), the PR/8-I38T mutant (H1N1, recombinant baloxavir-resistant strain), and the influenza B/Lee/40 virus strain. These compounds have novel chemical scaffolds and relatively small molecular weights and are suitable for optimization as lead compounds. Based on sequence and structure comparisons of PB2 CBDs of various influenza virus subtypes, we propose that the Phe323/Gln325, Asn429/Ser431, and Arg355/Gly357 mutations, particularly the Arg355/Gly357 mutation, have a marked impact on the selectivities of PB2 CBD-targeted inhibitors of influenza A and influenza B.
Keywords: influenza virus; inhibitor; polymerase basic protein 2; virtual screening.